MedlinePlus: heart problems associated with diabetes

The first row in the table of contents contains the following groups: learn more & Multimedia. Reference materials of PRA

View the original article here

MedlinePlus: heart problems associated with diabetes

The first row in the table of contents contains the following groups: learn more & Multimedia. Reference materials of PRA

View the original article here

Diabetes Detection

AppId is over the quota
AppId is over the quota

April 6, 2012 / Vol. 61 / No. RR–2
Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening for Inherited Metabolic Disorders
CE Available

This report provides recommendations for good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. The recommended practices address the benefits of using a quality management system approach, factors to consider before introducing new tests, establishment and verification of test performance specifications, the total laboratory testing process, confidentiality of patient information and test results, and personnel qualifications and responsibilities for laboratory testing for inherited metabolic diseases. These recommendations are intended for laboratories that perform biochemical genetic testing to improve the quality of laboratory services and for newborn screening laboratories to ensure the quality of laboratory practices for inherited metabolic disorders. These recommendations also are intended as a resource for medical and public health professionals who evaluate laboratory practices, for users of laboratory services to facilitate their collaboration with newborn screening systems and use of biochemical genetic tests, and for standard-setting organizations and professional societies in developing future laboratory quality standards and practice recommendations.

View the original article here

Diabetes drug injected once a week gets FDA approval:: Bydureon (long-acting exenatide)

From The NYTimes:


ONwTvUqrslM/T7AazOgHNTI/AAAAAAAAAM4/uaxyZsrCIa8/s320/Incretins.jpg" width="320" />The FDA has twice refused to approve the long-acting exenatide (: Bydureon) in 2010, with its most serious concern is that the drug could contribute to abnormal heart rhythm. There are security issues involving pancreatitis and thyroid cancer.
: BYDUREON is a longer-lasting version of Amylin's Byetta drug exists, which is injected twice a day. Another company, alkermes, has provided technology that releases slowly: Bydureon inside the body.
Byetta and Victoza: BYDUREON, are drugs called receptor agonists GLP-1, which mimic the effect of peptides glucagonlike-1, a hormone that increases the production of insulin when blood sugar is high.

Action Figure: DPP-4 inhibitors. Note that DPP-4 inactivates GLP-1 normally. DPP-4 inhibitors that block DPP-4, which in turn leaves GLP-1. Click to enlarge the picture. I did figure with Gliffy in 2006. Inhibitors of DPP-4 action diagram is widely used in many articles on Wikipedia, with my permission.
The main ingredient is Byetta exenatide: Bydureon, which is a hormone derived from the saliva to the Gila monster, a venomous lizard found in the southwest of the United States and Mexico.
Wholesale price: Bydureon would $323 for 4 doses, or about $ 4,200 a year. That is one of the approximately 3,400 for low dose of Victoza and $ 5,000 for the high dose.
References:
Diabetes drug injected weekly Wins FDA approval. NYTimes.
Comment by Twitter:
Vaughn Eyvazian @ Vaughnsays: increased compliance with pt!
Reinaldo b. @ basanezrx: but no one stays in the minimum dose of Victoza in my experience, and that is why most companies pay for ins Byetta instead. A shame the